CAMP4 Therapeutics (CAMP) vs Immuneering (IMRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Immuneering (IMRX) over the past year, gaining 16.7% versus a loss of 36.8%. Immuneering is the larger company by market cap ($239.1 million vs $230.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | IMRX |
|---|---|---|
| Share price | $3.67 | $3.69 |
| Market cap | $230.30M | $239.05M |
| 1-day change | -4.43% | -4.28% |
| YTD return | -37.36% | -41.34% |
| 1-year return | +16.72% | -36.82% |
| 5-year return | — | -84.47% |
| EPS (TTM) | $-2.32 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $8.48 |
| 52-week low | $2.86 | $3.60 |
| Distance from 52-week high | -52.65% | -56.43% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +188.01% | +364.69% |
| Average volume | 277.90K | 694.54K |
| Shares outstanding | 62.75M | 64.70M |
| Employees | 48 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed IMRX by 53.5 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
CAMP vs IMRX FAQ
Which is bigger, CAMP4 Therapeutics or Immuneering?
Immuneering (IMRX) is larger, with a market capitalization of $239.05M compared with $230.30M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or IMRX?
CAMP returned +16.72% over the past 12 months, compared with -36.82% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Immuneering in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.